The U.S. Food and Drug Administration (FDA) has approved the use of pembrolizumab (Keytruda) in combination with enfortumab vedotin (Padcev) for the perioperative treatment of patients with muscle-invasive bladder cancer (MIBC). This approval covers both neoadjuvant therapy given before surgery and adjuvant therapy given after surgery. The decision follows clinical data that showed improved outcomes for patients receiving this combination, according to a recent news report.

Key Takeaways

  • The FDA now allows pembrolizumab plus enfortumab vedotin for perioperative treatment of muscle-invasive bladder cancer.
  • This regimen is intended for use both before and after surgical removal of the bladder.
  • Patients with MIBC have a new targeted option that combines immunotherapy with an antibody-drug conjugate.

What Is Muscle-Invasive Bladder Cancer?

Bladder cancer begins when cells in the lining of the bladder grow uncontrollably. Muscle-invasive bladder cancer means the tumor has spread into the thick muscle layer of the bladder wall. This stage is more aggressive than non-muscle-invasive forms and carries a higher risk of spreading to other parts of the body. Standard treatment often involves surgery to remove the bladder, sometimes combined with chemotherapy. The new FDA-approved combination gives doctors an alternative to traditional chemotherapy before and after surgery.

How Do These Drugs Work?

Pembrolizumab is an immunotherapy drug that helps the body’s immune system recognize and attack cancer cells. It blocks the PD-1 pathway, which tumors use to hide from immune cells. Enfortumab vedotin is an antibody-drug conjugate that targets a protein called Nectin-4 found on bladder cancer cells. Once attached, it releases a chemotherapy-like toxin directly into the cancer cells. Used together, they attack the tumor through two different mechanisms. The FDA’s approval for perioperative use means patients can receive this combination before surgery to shrink tumors and after surgery to reduce the risk of recurrence.

What Does Perioperative Treatment Mean?

Perioperative therapy includes both neoadjuvant (pre-surgery) and adjuvant (post-surgery) phases. In the neoadjuvant phase, patients take the drugs for several weeks before surgery, aiming to shrink the tumor and make removal easier. After surgery, the adjuvant phase continues for a set period to eliminate any remaining cancer cells that may cause a relapse. This approach has become more common for muscle-invasive bladder cancer because it may improve long-term outcomes compared to surgery alone. The original report notes that the approval was based on studies showing that this combination led to better outcomes for patients.

What Did the Clinical Trial Show?

The news report did not provide detailed trial results, but it indicated that the FDA’s decision relied on data demonstrating improved outcomes for patients receiving pembrolizumab plus enfortumab vedotin. Clinical trials for advanced bladder cancer had previously shown that this combination can help shrink tumors and delay disease progression. The perioperative approval suggests that the benefits extend to earlier stages of the disease, giving patients a chance for better outcomes when used before and after surgery. Doctors will now be able to prescribe this regimen as an alternative to cisplatin-based chemotherapy, which some patients cannot tolerate.

What Does This Approval Mean for Patients?

For people diagnosed with muscle-invasive bladder cancer, this approval adds a powerful new tool to the treatment toolbox. It offers an option that combines two innovative drug classes and can be given in a hospital or clinic setting. Patients who are not good candidates for chemotherapy because of kidney problems or other health issues may especially benefit. The approval also highlights the growing role of immunotherapy and targeted therapies in bladder cancer care. As reported, the FDA’s green light marks a step forward in personalized treatment for this challenging disease.

Frequently Asked Questions

What is pembrolizumab?

Pembrolizumab is a type of immunotherapy called an immune checkpoint inhibitor. It works by blocking the PD-1 protein on T cells, which allows the immune system to better detect and attack cancer cells. It is used to treat several types of cancer.

What is enfortumab vedotin?

Enfortumab vedotin is an antibody-drug conjugate. It consists of an antibody that targets the Nectin-4 protein, which is often found on bladder cancer cells, attached to a chemotherapy agent. Once it binds to the cancer cell, it releases the drug directly inside.

What is muscle-invasive bladder cancer?

Muscle-invasive bladder cancer is a stage of bladder cancer in which the tumor has grown into the muscle layer of the bladder wall. It is more likely to spread than non-muscle-invasive forms and often requires aggressive treatment including surgery.

This is an original report by Vital Signs Today, informed by reporting from Google News. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.